NovaBridge Biosciences
NBP News Today: Stay Updated with the Latest NovaBridge Biosciences News in Real Time
Find NBP news now at Meyka AI. Stay informed with the latest NovaBridge Biosciences stocks updates, including price news, market analysis, and expert insights.
IDYA Maintained at Outperform by Wedbush April 2026
Wedbush maintained IDYA at Outperform, raising price target to $58 from $52 on April 14, 2026.
PCRX Analyst Rating Maintained at Buy by H.C. Wainwright
H.C. Wainwright maintains Buy rating on PCRX analyst rating, citing clearer real-world data in hip arthroplasty applications.
Gas Pipeline Threat Row: Serbia Says No Ukraine Link — April 06
Serbia intelligence rejects a Ukraine link to explosives near the TurkStream pipeline, spotlighting EU gas pipeline risks. Here is what it means for UK prices and investors.
Neurocrine Biosciences Close to $2.5B Acquisition of Soleno Therapeutics
We’re seeing a major move in biotech today. Neurocrine Biosciences is close to completing a deal to acquire Soleno Therapeutics in a transaction worth more than $2.5 billion, potentially rising to about $2.9 billion in cash. This deal is one of the most notable biotech acquisitions so far in 2026, and it aligns with Neurocrine’s growth strategy…
April 6: Serbia-Hungary Gas Pipeline Threat Sparks Sabotage Claims
Serbia gas risk rises after explosives were reported near a TurkStream link to Hungary. Orban alleges sabotage before a tight election, raising EU price volatility risk.
Pre-market loser KURN.SW Kuros Biosciences SIX Mar 2026 -6.14%: valuation risk
Pre-market look at KURN.SW stock down -6.14% on 25 Mar 2026 with Meyka AI forecast and valuation insight
Pre-Market Top Loser: GNCA stock at $0.0001 on NASDAQ, Chapter 11 fallout to watch
Pre-market: GNCA stock at $0.0001 on NASDAQ on 19 Mar 2026; Chapter 11 history, low liquidity, and Meyka AI forecast
C$0.035 WLLW.TO Willow Biosciences (TSX) market closed 18 Mar 2026: bounce risk
WLLW.TO stock closed C$0.035 on TSX 18 Mar 2026 with heavy volume and an oversold bounce setup
Jefferies Maintains Buy for Precision BioSciences (DTIL) March 13, 2026
Jefferies keeps Buy; DTIL analyst rating notes price target cut to $19 and near-term setup attractive